Abstract
The marked progress in controlling emesis caused by cisplatin characterizes the current status of antiemetic treatment for all chemotherapy. Cisplatin has provided a model for antiemetic studies. Strategies for controlling cisplatin-induced emesis are at least as successful when applied to other chemotherapy and persistent problems such as delayed emesis and the emesis associated with consecutive-day chemotherapy are also similar to or less severe than those observed with cisplatin. The purpose of this report is twofold: first to outline briefly therapy for cisplatin-induced emesis as illustrated by several new studies, and, second, to report on a new trial that incorporates some different strategies in the control of delayed emesis after cisplatin.
Publication types
-
Clinical Trial
-
Clinical Trial, Phase II
-
Randomized Controlled Trial
MeSH terms
-
Administration, Oral
-
Adult
-
Aged
-
Aged, 80 and over
-
Antiemetics / adverse effects
-
Antiemetics / therapeutic use*
-
Antineoplastic Agents / adverse effects*
-
Cisplatin / adverse effects*
-
Dexamethasone / adverse effects
-
Dexamethasone / therapeutic use
-
Dose-Response Relationship, Drug
-
Drug Administration Schedule
-
Drug Therapy, Combination
-
Female
-
Humans
-
Male
-
Metoclopramide / adverse effects
-
Metoclopramide / therapeutic use
-
Middle Aged
-
Ondansetron / adverse effects
-
Ondansetron / therapeutic use
-
Placebos
-
Time Factors
-
Vomiting / chemically induced*
-
Vomiting / prevention & control*
Substances
-
Antiemetics
-
Antineoplastic Agents
-
Placebos
-
Ondansetron
-
Dexamethasone
-
Metoclopramide
-
Cisplatin